Phase 1a, First-In-Human, Dose-Escalation Study of (+)-SJ000557733 (SJ733), an Oral, Novel Inhibitor of Plasmodium Falciparum Plasma Membrane Protein PfATP4

Trial Profile

Phase 1a, First-In-Human, Dose-Escalation Study of (+)-SJ000557733 (SJ733), an Oral, Novel Inhibitor of Plasmodium Falciparum Plasma Membrane Protein PfATP4

Recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Nov 2017

At a glance

  • Drugs SJ 733
  • Indications Malaria
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Acronyms BUZZOFF
  • Most Recent Events

    • 09 Nov 2017 Planned End Date changed from 31 Dec 2017 to 1 Jul 2018.
    • 09 Nov 2017 Planned primary completion date changed from 31 Dec 2017 to 1 Jul 2018.
    • 12 Jul 2017 Planned End Date changed from 30 Jun 2017 to 31 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top